tailieunhanh - Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in clinical development or on the market. However, adverse events and resistance associated with those proteasome inhibitors indicate the need for a new generation of drugs. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN